You are correct.
Conclusions
I consider that the market will favourably re-rate the share-price in the next year or two.
In my opinion the drugs are of proven value, only the mode of administration is novel, and likely to confer market advantages.
There has already been quite extensive research and development carried out.
The company appears to be lean, and has been able to survive on a limited budget.
I propose to take a position in the company myself.
lost posts, page-8
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
-0.003(1.54%) |
Mkt cap ! $168.2M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 16.5¢ | 15.5¢ | $214.8K | 1.322M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 691512 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 481234 | 8 |
View Market Depth
| Last trade - 13.38pm 03/10/2024 (20 minute delay) ? |
| ALA (ASX) Chart |